SOPHiA GENETICS SA (SOPH)
Market Cap | 303.99M |
Revenue (ttm) | 64.18M |
Net Income (ttm) | -72.98M |
Shares Out | 65.38M |
EPS (ttm) | -1.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 36,066 |
Open | 4.655 |
Previous Close | 4.560 |
Day's Range | 4.510 - 4.660 |
52-Week Range | 2.130 - 7.370 |
Beta | 1.06 |
Analysts | Strong Buy |
Price Target | 7.33 (+57.63%) |
Earnings Date | Aug 6, 2024 |
About SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, Nor... [Read more]
Financial Performance
In 2023, SOPH's revenue was $62.37 million, an increase of 31.14% compared to the previous year's $47.56 million. Losses were -$78.98 million, -9.68% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 57.63% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/p/p/press8-2542511.jpg)
SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native ...
![](https://cdn.snapi.dev/images/v1/3/s/press9-2541975.jpg)
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native h...
![](https://cdn.snapi.dev/images/v1/o/y/conf19-2538447.jpg)
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024
BOSTON and ROLLE, Switzerland , July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its ...
![](https://cdn.snapi.dev/images/v1/6/n/press4-2509588.jpg)
India-Based Dhiti Omics is Now Live on SOPHiA DDM™
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland , July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud...
![](https://cdn.snapi.dev/images/v1/f/m/press3-2492912.jpg)
SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting
BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that it...
![](https://cdn.snapi.dev/images/v1/i/0/press8-2492130.jpg)
SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application
Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland , June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nas...
![](https://cdn.snapi.dev/images/v1/b/u/press13-2477205.jpg)
SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native heal...
![](https://cdn.snapi.dev/images/v1/q/u/press17-2454315.jpg)
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care
New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland , May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasd...
![](https://cdn.snapi.dev/images/v1/d/c/press13-2451771.jpg)
SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland , May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS ...
![](https://cdn.snapi.dev/images/v1/g/m/press20-2439767.jpg)
SOPHiA GENETICS Announces Instituto Mário Penna as New Customer
The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform BOSTON and ROLLE, Switzerland , May 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-n...
![](https://cdn.snapi.dev/images/v1/s/q/press3-2434156.jpg)
Klinikum Klagenfurt am Wörthersee is Live with SOPHiA GENETICS
The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland , May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a clou...
![](https://cdn.snapi.dev/images/v1/u/i/press17-2414101.jpg)
SOPHiA GENETICS Reports First Quarter 2024 Results
Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed
![](https://cdn.snapi.dev/images/v1/e/4/conf1-2399310.jpg)
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer an...
![](https://cdn.snapi.dev/images/v1/w/f/conf7-2385714.jpg)
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial r...
![](https://cdn.snapi.dev/images/v1/w/x/press19-2384726.jpg)
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa BOSTON and ROLLE, Switzerland , April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a c...
![](https://cdn.snapi.dev/images/v1/e/k/press12-2375277.jpg)
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland , April 17, 2024 /PRNewswire/ -...
![](https://cdn.snapi.dev/images/v1/i/9/press6-2355690.jpg)
SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership
The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland , April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native s...
![](https://cdn.snapi.dev/images/v1/a/6/press2-2352357.jpg)
Laboratorio Barnafi-Krause is Live on SOPHiA DDM™
The Chile-based Laboratory is using SOPHiA GENETICS' platform to advance its research capabilities with blood disorders BOSTON and ROLLE, Switzerland , April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (N...
![](https://cdn.snapi.dev/images/v1/s/z/press12-2333278.jpg)
SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada
University of Saskatchewan's (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™ Platform to advance research on ovarian cancer care BOSTON and ROLLE, Switzerland , March 20, 2024 /...
![](https://cdn.snapi.dev/images/v1/l/q/press10-2326029.jpg)
SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration
New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland , March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH)...
![](https://cdn.snapi.dev/images/v1/j/v/conf2-2313677.jpg)
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial ...
![](https://cdn.snapi.dev/images/v1/o/l/press19-2308026.jpg)
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 Strong momentum to continue in 2024 as SOPHiA GEN...
![](https://cdn.snapi.dev/images/v1/g/e/press5-2288500.jpg)
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Co-founder and Ch...
![](https://cdn.snapi.dev/images/v1/m/r/conf10-2283967.jpg)
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release i...
![](https://cdn.snapi.dev/images/v1/o/d/press9-2264007.jpg)
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID , Feb. 7, 2024 /PRNewswire/ -- SOPHi...